1. Scrip
  2. >>Business

Boehringer Ingelheim Limbering Up With Humira Biosimilar

 
• By Eleanor Malone

Presenting equivalence data at EULAR for its biosimilar version of the world's best-selling drug, Humira, Boehringer Ingelheim is optimistic about its position in a crowded field. Karsten Kissel, head of global medical affairs biosimilars for the German group, spoke to Scrip.

Races
Boehringer Ingelheim early to gates in crowded field • Source: Shutterstock

Boehringer Ingelheim GMBH has presented pivotal Phase III results for BI 695501, its biosimilar version of AbbVie Inc.'s top-selling anti-TNF drug Humira (adalimumab), at the Annual European Congress of Rheumatology (EULAR) in Madrid, Spain. The results of VOLTAIRE-RA demonstrate clinical equivalence of '501 and Humira, completing the body of evidence needed to prove biosimilarity and earn approval from regulators. The candidate has already been accepted for filing in both the EU and US, but the company is not commenting on its expectations for the timing of approval decisions. In any case, commercial launch is likely to be delayed by AbbVie's patent defenses.

Humira is the world's top-selling drug, generating revenues of $16.5bn for AbbVie in 2016, and there are multiple biosimilar contenders...

More from Business

Positive Fabry Data Should Smooth Way For Sangamo’s Partnering Efforts

 
• By Alaric DeArment

The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.

Industry’s Vaccines Pipeline In A Changing Regulatory Landscape

 
• By Jessica Merrill

More than a dozen vaccines for infectious diseases are in Phase III development across the industry, as the US regulatory environment brings increased uncertainty.

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

 
• By Kevin Grogan

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.

Stock Watch: When The Biotech Bandwagon Music Stops

 
• By Andy Smith

The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.

More from Scrip

Lilly’s Muscle Builder Looks Strong In GLP-1 Obesity Combo

 
• By Andrew McConaghie

Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

 
• By Sushmita Panda

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.

Saudi Arabia Plans Advanced Manufacturing Campus Under Biotech Drive

 
• By Aakash Babu

A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.